



Amendments to the Claims

Claims 1-14 (Cancelled)


Claim 15. (Currently Amended) A compound selected from the group consisting of:
 6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinimidic acid ethyl ester




N-Hydroxy-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide




6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinamide




{4-[5-(4,5-Dihydro-1H-imidazol-2-yl)-pyridin-2-yloxy]-benzyl}-(3-methyl-butyl)-amine




{4-[5-(4,5-Dihydro-1H-imidazol-2-yl)-pyridin-2-yloxy]-benzyl}-(2-thiophen-2-yl-ethyl)amine




(3-Methyl-butyl)- {4-[5-(4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl)-pyridin-2-yloxy]-benzyl}-amine




(3-Methyl-butyl)- {4-[5-(1,4,5,6-tetrahydropyrimidin-2-yl)[[2-yl]]-pyridin-2-yloxy]-benzyl}-amine




N-Cyano-6- {4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide




(3-Methyl-butyl)- {4-[5-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyl}-amine




{4-[5-(1H-Imidazol-2-yl)-pyridin-2-yloxy]-benzyl}-(3-methyl-butyl)-amine




N-(2,2-Dimethoxy-ethyl)-6-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide




6-{4-[3-Methyl-butylamino)-methyl]-phenoxy}-benzoxisoxazol-3-ylamine




6-{4-[(3,3-Dimethyl-butylamino)-methyl]-phenoxy}-benzo[d]isoxazol-3-ylamine




6-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-benzo[d]isoxazol-3-ylamine




6-(4-{[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-benzo[d]isoxazol-3-ylamine



6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-1H-indazol-3-ylamine



6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinic acid dihydrochloride



and a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer and diastereomeric mixture thereof.

Claim 16. (Currently Amended) A compound according to [[Claim 1]] Claim 15 wherein the pharmaceutically acceptable salt is the hydrochloric acid salt, the methanesulfonic acid salt, hydrobromide salt, the bisulfate salt or tartaric acid salt.

Claim 17. (Cancelled).

Claim 18. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 15 in association with a carrier, diluent and/or excipient.

Claim 19. (Cancelled)

Claim 20. (Currently Amended) A method of treating [[and/or preventing]] obesity [[and Related Diseases]] comprising administering a therapeutically effective amount of a compound of [[formula I]] Claim 15 to a patient in need thereof.

Claim 21. (Cancelled).

Claim 22. (Cancelled)

Claim 23. (Currently Amended) A method of suppressing appetite in a patient in need thereof, comprising administering a therapeutically effective amount of a compound of [[formula I]] Claim 15.

Claim 24. (Cancelled)

Claim 25. (Cancelled)